Lantheus Holdings has completed its acquisition of Life Molecular Imaging and appointed the company's former CEO and managing director, Ludger Dinkelborg, PhD, as head of research and development, effective August 1.
Dinkelborg will oversee clinical development, regulatory affairs, clinical operations, program management, and AI/biomarkers solutions with a focus on oncology, neurology, and cardiology, according to Lantheus.
The purchase included Life Molecular's florbetaben F-18 PET imaging agent (Neuraceq) for detecting beta-amyloid plaques in patients being evaluated for Alzheimer’s disease. The addition builds on Lantheus' June 2024 acquisition of the global rights to Life Molecular's clinical-stage radiotherapeutic and radiodiagnostic pair, lutetium-177 DOTA-RM2 and gallium-68 DOTA-RM2.
The all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments was announced in January.
